GREENWICH LIFESCIENCES, INC. Additional Paid in Capital, Common Stock
GREENWICH LIFESCIENCES, INC. (GLSI) had Additional Paid in Capital, Common Stock of $99.85 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-11
- 2026-06-30: Additional Paid in Capital, Common Stock $99.85M.
- 2026-03-31: Additional Paid in Capital, Common Stock $98.05M.
- 2025-12-31: Additional Paid in Capital, Common Stock $87.48M.
- 2025-09-30: Additional Paid in Capital, Common Stock $79.76M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $99.85M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $98.05M 10-Q · filed 2026-06-04 |
| 2025-12-31 | $87.48M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $79.76M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $74.86M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $70.71M 10-Q · filed 2025-05-20 |
| 2024-12-31 | $68.67M 10-K · filed 2026-06-01 |
| 2024-09-30 | $63.08M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $61.31M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $57.95M 10-Q · filed 2024-05-20 |
| 2023-12-31 | $57.05M 10-K · filed 2025-04-15 |
| 2023-09-30 | $56.46M 10-Q · filed 2023-10-19 |
| 2023-06-30 | $55.86M 10-Q · filed 2023-08-21 |
| 2023-03-31 | $55.27M 10-Q · filed 2023-05-22 |
| 2022-12-31 | $54.67M 10-K · filed 2024-04-15 |
| 2022-09-30 | $54.08M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $53.32M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $55.12M 10-Q · filed 2022-05-20 |
| 2021-12-31 | $60.47M 10-K · filed 2023-03-31 |
| 2020-12-31 | $56.70M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |